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Introduction: HIV makes a signiﬁcant contribution to maternal
mortality, and women living in sub-Saharan Africa are most affected.
International commitments to eliminate preventable maternal mor-
tality and reduce HIV-related deaths among pregnant and postpartum
women by 50% will not be achieved without a better understanding
of the links between HIV and poor maternal health outcomes and
improved health services for the care of women living with HIV
(WLWH) during pregnancy, childbirth, and postpartum.
Methods: This article summarizes priorities for research and
evaluation identiﬁed through consultation with 30 international
researchers and policymakers with experience in maternal health and
HIV in sub-Saharan Africa and a review of the published literature.
Results: Priorities for improving the evidence about effective
interventions to reduce maternal mortality and improve maternal
health among WLWH include better quality data about causes of
maternal death among WLWH, enhanced and harmonized program
monitoring, and research and evaluation that contributes to improv-
ing: (1) clinical management of pregnant and postpartum WLWH,
including assessment of the impact of expanded antiretroviral
therapy on maternal mortality and morbidity, (2) integrated service
delivery models, and (3) interventions to create an enabling social
environment for women to begin and remain in care.
Conclusions: As the global community evaluates progress and
prepares for new maternal mortality and HIV targets, addressing the
needs of WLWH must be a priority now and after 2015. Research
and evaluation on maternal health and HIV can increase collabora-
tion on these 2 global priorities, strengthen political constituencies
and communities of practice, and accelerate progress toward
achievement of goals in both areas.
Key Words: HIV, maternal health, maternal mortality, research
priorities, women’s health, pregnancy
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INTRODUCTION
Nearly 18 million women are living with HIV world-
wide, and more than 90% of pregnant women living with HIV
(WLWH) reside in sub-Saharan Africa.
1,2 Globally, HIV and
complications related to pregnancy remain the 2 leading causes
of death for women of reproductive age.
3 Global maternal mor-
tality has been reduced from an estimated 543,000 deaths in
1990 to 287,000 deaths in 2010. However, in the same period,
maternal mortality seems to have increased in 8 sub-Saharan
African countries with high HIV prevalence.
4 Without timely
antiretroviral therapy (ART), WLWH in sub-Saharan Africa are
approximately 8 times as likely to die during pregnancy or the
postpartum period as HIV-negative women.
5–7 Before wider
availability of ART, about 1 quarter of pregnancy-related deaths
in the region were attributable to HIV.
6 International commit-
ments to eliminate preventable maternal mortality
8 and reduce
HIV-related deaths among pregnant and postpartum women by
50%
9 will not be achieved without a better understanding of the
links between HIV and poor maternal health outcomes and
improved health services for the care of WLWH during preg-
nancy, childbirth, and postpartum.
Research, monitoring, and evaluation are needed to
understand the relationships between HIV and increased
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adoption of and sustained support for interventions that work,
and generate solutions that address persistent barriers to the
maternal health of WLWH. The context for the questions
identiﬁed in this research and evaluation agenda includes
impressive but uneven progress on providing antenatal HIV
testing and ART to prevent vertical (mother-to-child) HIV
transmission in sub-Saharan Africa.
10 Additionally, new treat-
ment guidelines recommend earlier initiation of ART for all
adults, and a growing number of countries are moving
towards initiation of lifelong treatment for all pregnant and
breastfeeding WLWH, regardless of CD4 count (Option
B+).
11 The impact of these treatment changes on maternal
mortality and morbidity is still unclear. At the same time,
signiﬁcant numbers of treatment-eligible women who learn
they are living with HIV during pregnancy in sub-Saharan
Africa do not begin ART,
12,13 and for those who do, retention
in care
14,15 and postpartum ART adherence
16 are suboptimal.
The current situation suggests that services better aligned to
women’s needs and enabling social environments are critical
for more women to begin and remain in care.
Beyond ART, coverage of interventions necessary to
improve the maternal health of all women, but which are
particularly crucial for WLWH, such as screening and
treatment for tuberculosis
17 and malaria
18 and provision of
contraceptive information and services,
19 is insufﬁcient. Preg-
nancy and HIV both increase women’s susceptibility to acquir-
ing malaria and to developing active tuberculosis disease.
20–22
Coinfection with HIV and either malaria or tuberculosis are
also associated with increased risk of maternal death compared
with women who have tuberculosis or malaria but are not
living with HIV.
23,24 Reducing unintended pregnancies among
WLWH constitutes primary prevention of vertical transmission
and maternal mortality and morbidity, but although 66%–92%
of WLWH in sub-Saharan Africa report not wanting another
child (now or ever), only 20%–43% are using contraception.
25
Finally, although the efﬁcacy of ART for preventing sexual
26
and vertical HIV transmission
27 holds promise for safer repro-
ductive opportunities for WLWH, limited attention has been
focused on strategies to support safer conception among HIV-
serodiscordant couples in resource-constrained settings.
28,29
Identiﬁcation of the Research and
Evaluation Priorities
In June 2013, 56 international maternal health and HIV
researchers and policy implementers were convened by the
Maternal Health Task Force, the United States Agency for
International Development, and the United States Centers for
Disease Control and Prevention to share emerging evidence
and identify priority knowledge gaps for improving pro-
grammatic responses to maternal health in contexts of high
HIV prevalence. After this 2-day meeting, 30 researchers and
policy implementers participated in a day-long meeting
dedicated to reaching consensus on research and evaluation
priorities for HIV and maternal health in sub-Saharan Africa.
In addition to experience and technical expertise in HIV and
maternal health, criteria for selecting the invited experts
included representation of institutions from sub-Saharan
Africa, North America, and Europe and a range of disciplin-
ary backgrounds. Please see www.mhtf.org to consult the
meeting agenda, presentations, and participant list. After
a facilitated discussion of research and evaluation priorities,
the experts divided into 3 groups tasked with reaching con-
sensus on 4 priority areas for research and evaluation. Repe-
tition of identiﬁed priorities allowed clustering in 3 broad
areas for research and evaluation that were agreed on by
consensus: (1) clinical management of pregnant and postpar-
tum WLWH to address the leading causes of maternal death
and evaluate the impact of expanded ART on maternal mor-
tality and morbidity, (2) integrated service delivery models
that simultaneously provide HIV screening and/or treatment
and address malaria, tuberculosis, and/or the reproductive
health of WLWH to optimize maternal health outcomes,
and (3) an enabling social environment for women to begin
and remain in care. The international working group that
authored this article was formed to further develop the
research and evaluation agenda and a conceptual framework
(Fig. 1). Subsequently, narrative reviews of the peer-reviewed
literature, relevant international guidelines and selected docu-
ments from the gray literature were conducted for each of the
identiﬁed subtopics to summarize the existing evidence and
knowledge gaps and generate additional speciﬁc research
questions. The full working paper provides a comprehensive
review of the literature and a detailed discussion of the pro-
posed research and evaluation agenda.
30 This article synthe-
sizes broad research and evaluation questions that should be
addressed to improve the maternal health of WLWH and
provides illustrative examples. Table 1 outlines additional
research questions.
The 3 thematic areas focus on different levels of the
social and programmatic context relevant for HIV and
maternal health (Fig. 1) as follows: (1) the “individual” level
is focused on the clinical management and maternal health
outcomes of WLWH; (2) the “health system” level considers
how multiple priority health needs can best be addressed in
resource-constrained health systems; and (3) at the “society”
level, the intent is to assess how interventions that address
gender and HIV-related discrimination and create a supportive
social environment affect women’s linkage to and retention in
health services. Evidence-based interventions will resonate
positively across all 3 levels. For instance, better information
about the causes of maternal death among WLWH can inform
clinical management and health system resource allocation.
Subsequent reductions in maternal deaths can create more
community demand for services, creating a positive cycle.
Similarly, when the social context enables women to access
and continue HIV care and adhere to ART, individual mor-
bidity and mortality, sexual and vertical HIV transmission,
and development of antiretroviral resistance will be reduced.
Individual and community health outcomes and the sustain-
ability of ART programs will be improved.
IMPROVING DATA AVAILABILITY AND QUALITY
Three overarching issues were identiﬁed regarding data
availability and quality: the lack of good quality data on the
causes of maternal death, the need for enhanced program
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matic interventions for pregnant and postpartum WLWH, and
the need for program evaluation to report on health outcomes
in addition to process indicators. To improve availability and
quality of maternal death data, recording all maternal deaths
that occur in facilities and improving the quality of death
certiﬁcates is a priority.
31 Implementing maternal death
surveillance and response, which links facility- and
community-based notiﬁcation and investigation to national
health information systems and includes a multidisciplinary
process for making recommendations, is strongly advised.
32
The existence of signiﬁcant errors in descriptions of cause of
maternal death (even at tertiary level facilities) indicates the
need for more autopsy studies. In addition, the large numbers
of women who deliver outside of facilities in most countries
in sub-Saharan Africa points to the need for further develop-
ment of minimally invasive autopsies and improvement of
verbal autopsy tools for use in the community.
Harmonized monitoring that identiﬁes whether women are
(1) living with HIV and (2) pregnant or postpartum would permit
evaluation of the effects of programs on the maternal health of
WLWH. Tuberculosis provides an example of the value of this
approach. Ensuring that people living with HIV are screened for
tuberculosis and given prophylactic treatment is a core activity
for HIV treatment and tuberculosis control programs. Pregnant
WLWH have an elevated risk of developing tuberculosis disease
and of maternal death, but many information systems for
monitoring tuberculosis prevention and treatment among people
with HIV do not identify pregnant and postpartum women.
Finally, evaluation research tends to report on process
outcomes, such as coverage, rather than health outcomes, and
in general, does not report on relatively rare events, such as
maternal mortality. The expert meeting and literature review
identiﬁed the need to increase reporting of maternal health
outcomes as part of program evaluation. Indeed, many of the
interventions identiﬁed as priorities for evaluation have had
FIGURE 1. Conceptualization of research and evaluation priorities for eliminating HIV-related maternal mortality.
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contraceptives or reduction of intimate partner violence
(IPV), but have not been evaluated for their effects on
maternal morbidity and mortality among WLWH.
INDIVIDUAL: CAUSE OF MATERNAL DEATH
AND CLINICAL MANAGEMENT OF PREGNANT
AND POSTPARTUM WLWH
How Will Rates and Causes of Morbidity and
Mortality During Pregnancy and the
Postpartum Period be Affected by Increased
Availability of ART for WLWH?
Tracking maternal health outcomes to assess the impact
of ART on excess maternal morbidity and mortality is
a priority as millions of WLWH begin and remain on
treatment. Evidence from sub-Saharan Africa indicates that
earlier initiation and longer duration of ART reduces the risk
of maternal death among WLWH. When South Africa began
initiating ART at a CD4+ cell count of #350 cells per micro-
liter rather than at #200 cells per microliter, an 18% reduc-
tion in the institutional maternal mortality ratio for WLWH
was observed during the ﬁrst year.
33 In Mozambique and
Malawi, more than 30 days of ART before delivery has been
associated with reduced risk of death during childbirth and
postpartum.
34 However, data from South Africa indicate high-
er maternal mortality rates among WLWH compared with
HIV-negative women even when they are receiving ART,
35
TABLE 1. Priority Research and Evaluation Questions to
Improve the Maternal Health of WLWH
Individual: Cause of Maternal Death and Clinical Management of
Pregnant and Postpartum WLWH
How will rates and causes of morbidity and mortality during pregnancy and
the postpartum period be affected by increased availability of ART for
WLWH?
What is the impact of ART on maternal morbidity and mortality caused by
or associated with sepsis, obstetric hemorrhage, hypertension, anemia,
malaria, pneumonia, and tuberculosis? What are the safest and the most
effective clinical protocols to address these conditions among pregnant
and postpartum WLWH? Are they as effective for WLWH as HIV-
negative women?
Are ART-related adverse events more common or severe during
pregnancy? Are side effects associated with reduced adherence among
pregnant women?
How does long-term ART affect maternal micronutrient status, particularly
as it relates to preconceptional health for future pregnancies?
What antibiotic protocols are most effective for preventing puerperal sepsis
among WLWH, including for emergency cesarean sections? What
policies and provider training prevent unnecessary elective cesarean
sections among WLWH?
Is hemorrhage more severe among WLWH than HIV-negative women after
controlling for the presence of anemia?
Will timely diagnosis and treatment of malaria and tuberculosis reduce
prevalence and severity of anemia among pregnant and postpartum
WLWH?
Is routine iron supplementation without verifying the presence of anemia
warranted for pregnant women in areas where there is a high prevalence
of both malaria and HIV? Does ART modify effects of iron
supplementation on HIV and malarial replication? Is nutritional
supplementation of pregnant and lactating WLWH in resource-limited
settings necessary, particularly if they are receiving ART?
What are the microbiological causes of pneumonia in pregnant WLWH?
Is cotrimoxazole as effective as sulfadoxine–pyrimethamine for
Intermittent Preventive Treatment of Malaria in Pregnancy in WLWH?
What are the best prophylactic regimens for malaria among WLWH?
What are the optimal clinical protocols for treating pregnant WLWH
who are taking ART and who also have severe malaria or multidrug
resistant tuberculosis?
Health System: Integrated Health Service Delivery
What are the most effective models for providing integrated services and
how will integrated services affect the maternal health of WLWH?
What are the most effective models for harmonizing policy and
programmatic guidelines to integrate crucial services (ART,
contraceptive information and provision, safer conception, malaria, and
tuberculosis screening and treatment)?
What are the advantages and disadvantages of integrated service delivery
for quality of care, clinical effectiveness, and coverage of core maternal
health and HIV services and the additional intervention?
What is the effect of task shifting on uptake and quality of care?
What is the effect of integrated service delivery on client and provider
satisfaction and retention?
What are the best screening questions and diagnostic methods for
improving detection of tuberculosis among pregnant WLWH?
How do educational programs for health care providers and counseling for
pregnant women to inform them about the safety of prophylactic
treatment for tuberculosis affect coverage?
Does training providers working in prenatal care to identify and manage
Immune Reconstitution Inﬂammatory Syndrome improve clinical
outcomes?
TABLE 1. (Continued) Priority Research and Evaluation
Questions to Improve the Maternal Health of WLWH
What models of counseling and service delivery increase access to and
uptake of contraceptive methods, including long-acting reversible
contraceptives and dual protection, while ensuring respect for
reproductive rights? What is the role of community and community–
facility collaborations in expanding access and uptake among WLWH
and their partners?
Are postpartum immunization visits an optimal time for providing
contraception information and services to WLWH?
How safe, effective, and acceptable to WLWH, their male partners, and
health care providers are biomedical interventions (including “treatment
as prevention,” pre-exposure prophylaxis and medical male circumcision
for an HIV-negative male partner) and behavioral interventions
(including manual insemination and timing intercourse to peak fertility)
to support safer conception?
Society: Create an enabling Environment for Women to Begin and
Continue in MCH and HIV Care
Do programs designed to reduce disrespect and abuse in maternity care,
HIV-related stigma and discrimination, IPV, and increase supportive
involvement of male partners improve maternal health outcomes?
What additional rights-promoting interventions and programs to address
social determinants of health are needed to promote equitable access and
improved maternal health outcomes for heterogeneous groups of
WLWH?
How will programs that seek to create an enabling environment affect
uptake and retention in MCH and HIV care among WLWH who are
disproportionately affected by the HIV epidemic, such as sex workers
and drug users?
Bold indicates heading.
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ating ART in Uganda found elevated risk of pregnancy-
related mortality when pregnancy and the 1-year postpartum
period were treated as a time-dependent risk factor.
36 Data
from the United States also indicate a persistently elevated
risk of maternal morbidity and mortality among WLWH in
the ART era.
37 More studies, including cohort studies that
allow valid comparisons by controlling for the health status
of different groups of WLWH and that allow adjusted com-
parisons with HIV-negative women, are needed to tease out
the relationships between HIV, pregnancy, time on ART,
immune status, and maternal morbidity and mortality. As
more countries offer lifelong ART for all pregnant and breast-
feeding WLWH, it is critical to develop surveillance systems
to track potential negative and positive effects of ART on
women and infants.
What Are the Safest and Most Effective
Clinical Protocols to Address the Leading
Causes of Maternal Morbidity and Mortality
Among WLWH?
Tuberculosis, malaria, pneumonia, and sepsis are the
leading causes of maternal death among WLWH.
38–40 Preva-
lence of anemia among pregnant WLWH is high and contrib-
utes to poor maternal and infant health outcomes.
41–43 Data
about greater incidence of hypertension or obstetric hemorrhage
and outcomes for pregnant WLWH are inconclusive.
44–49
Research to improve the prevention and clinical management
of the leading causes of maternal morbidity and mortality
among WLWH is needed. To exemplify, WLWH have 3 times
the risk of puerperal sepsis as compared with HIV-negative
women and a 6-fold greater risk when delivery is by caesar-
ean.
44 Maternal death audits in South Africa have identiﬁed an
institutional maternal mortality ratio due to sepsis of 24.2
among WLWH as compared with 4.1 per 100,000 live births
for HIV-negative women.
50 Results from studies that examined
provision of prophylactic antibiotics to WLWH before or dur-
ing delivery have been mixed.
51,52 Additional research is
needed to inform sepsis prevention for WLWH during labor
and delivery and as part of postpartum and postabortion care, as
well as to elucidate the relationships between puerperal sepsis,
immune status, and ART. Similar questions exist for other
causes of maternal morbidity and mortality among WLWH
(Table 1).
HEALTH SYSTEM: INTEGRATED HEALTH
SERVICE DELIVERY
What Are the Most Effective Models for
Providing Integrated Services and How Will
Integrated Services Affect the Maternal
Health of WLWH?
The promise of integrated service delivery is that
meeting women’s multiple health needs at a single point-of-
care, possibly during a single visit and potentially by the same
providers, can optimize women’s contact with the health sys-
tem and more effectively use scarce human and ﬁnancial
resources. Providing ART within maternal health services
and eliminating barriers to ART initiation, for example by
offering point-of-care CD4 testing
53 or eliminating CD4 testing
before initiation of ART,
54 has been shown to dramatically
increase uptake of ART among pregnant and breastfeeding
women.
55,56 Reviews of integration of interventions needed
to prevent vertical HIV transmission with other maternal and
child health (MCH) services have identiﬁed generally positive
results in terms of coverage, but few studies provide informa-
tion on health outcomes.
57,58 Similarly, provision of contracep-
tives in HIV services and as a routine part of postnatal care has
shown increased uptake by WLWH,
59–61 but information about
how these interventions affect unintended pregnancies or other
health outcomes is lacking.
62 Despite the overall positive
impact, individual studies that identify negative effects in some
settings, for instance, drops in child immunization rates in rural
clinics when offer of HIV testing was added to immunization
visits,
63 deserve attention. There are also outstanding questions
about the point on the MCH and HIV care continuum at which
to provide services. For example, if WLWH begin ART in
MCH services, when and how is the transition to chronic
HIV care most successfully accomplished? Research and eval-
uation priorities include monitoring to ensure that service inte-
gration does not compromise the quality and coverage of core
MCH and HIV services and medium-term assessment of health
outcomes. Studies that evaluate the impact of adding other care
components to MCH and HIV services, such as safer concep-
tion and contraceptive services, and malaria and tuberculosis
prevention and treatment are also needed.
Increasing the quality of services and the number of
interventions provided requires strengthening MCH and HIV
services and ensuring adequate human resources. This strength-
ening is particularly important in the context of increased
demands for ART provision to greater numbers of pregnant
and breastfeeding WLWH and guidelines recommending earlier
initiation of treatment for all people living with HIV. In addition,
the skills required to deliver different services, for instance, HIV
treatment adherence counseling or diagnosis and management of
tuberculosis may differ from the skills required to deliver high-
quality antenatal and obstetric care. As task shifting is imple-
mented, evaluation is needed to assess health care stafﬁng needs
and skill level and optimal provider mix to deliver interventions
safely and effectively while retaining health care providers on the
job and pregnant and postpartum women in care.
Preconception counseling and safer conception strategies
for women affected by HIV provide examples of the type of
research and evaluation needed to guide the integration of service
delivery. When and where on the continuum of MCH and HIV
services should information about biomedical and behavioral
interventions and services to support safer conception be offered
to WLWH and to serodiscordant couples? How prepared are
different cadres of HIV and MCH health care providers and
community members to provide safer conception strategies?
What facility- and community-based models are feasible and
what resources are needed to ensure quality and coverage?
Implementation research is needed to answer these questions and
to assess the impact of information and service provision on
reproductive behaviors, vertical and sexual HIV transmission,
and maternal health outcomes. Additional questions about
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WLWH and to prevent, diagnose, and treat tuberculosis and
malaria with MCH and HIV services are noted in Table 1.
SOCIETY: CREATE AN ENABLING
ENVIRONMENT FOR WOMEN TO BEGIN AND
CONTINUE IN MCH AND HIV CARE
Do Programs Designed to Reduce Disrespect
and Abuse in Maternity Care, HIV-Related
Stigma and Discrimination, IPV, and Increase
Supportive Involvement of Male Partners
Improve Maternal Health Outcomes?
Gender discrimination and HIV-related stigma violate
human rights and contribute to poor health outcomes, in part
by creating barriers to women’s utilization of essential mater-
nity and HIV services. Anticipation or experience of disre-
spect and abuse in maternity care and HIV-related stigma and
discrimination, including internalized stigma, have been asso-
ciated with avoidance of skilled delivery, refusal of antenatal
HIV testing, and for WLWH, not enrolling in HIV services,
and reduced adherence to ART for prevention of vertical HIV
transmission.
64–66 One of the most egregious forms of gender
discrimination, Intimate Partner Violence (IPV), is associated
with increased likelihood of acquiring and living with HIV
66–68
and with poor reproductive health outcomes among all
women.
69–72 Qualitative research indicates that experiencing
IPV can be a barrier to accessing HIV care and ART adherence
for women in Africa.
73 Studies from the United States and
Canada associate IPV with reduced ART adherence, detectable
viral load, and less engagement in HIV care.
74–76 There is an
urgent need to evaluate if facility- and community-based inter-
ventions that reduce disrespect and abuse during childbirth,
HIV-related stigma, and IPV result in improved uptake and
retention in care and better maternal health outcomes.
64,77–81
Interventions, such as IMAGE and Stepping Stones, are par-
ticularly promising as they have been shown to simultaneously
reduce IPV and HIV-related stigma and increase measures of
women’se m p o w e r m e n t ,
80,81 indicating the potential to address
multiple social determinants simultaneously.
Research and evaluation of male involvement in HIV
and MCH care is a related priority. When men attend prenatal
care visits with their female partners and choose to test for
HIV or women disclose their HIV status to male partners
during pregnancy, male involvement has been associated with
improved implementation of interventions to prevent vertical
HIV transmission.
82–84 Similarly, when women choose to dis-
close their HIV status, family-centered care has successfully
engaged men and supported women to remain in care.
85 How-
ever, how best to involve men systematically is a knowledge
gap. For example, while some models of promoting couple
counseling and HIV testing during pregnancy show promise
for engaging men and assisting women with safe disclosure,
86
others have resulted in half of the pregnant women asked to
bring their male partner not returning for antenatal care.
87
Research is needed to develop and evaluate programs that
involve male partners while safeguarding women’s access
to and retention in care, safety, and autonomy.
In addition, policymakers and programmers should
seriously consider the evidence associating participatory
women’s groups with reduced maternal mortality,
88 and show-
ing that community mobilization and peer support increase
supply of, demand for, and implementation of interventions
to prevent vertical HIV transmission, in addition to improving
pregnant and postpartum WLWH’s retention in care.
15,89–91
Existing evidence indicates that further investment in and eval-
uation of strategies that actively involve and engage commu-
nity members, including people living with HIV, is warranted.
Interventions designed to create an enabling environment
for women to begin and remain in care and treatment should be
sensitive to the diversity of women’s experiences and needs,
including those of women who may face additional barriers
because of age, civil status, ethnicity, drug use, involvement in
sex work, or other factors. Evaluation should consider proxi-
mate measures, such as uptake of services, retention in care,
disclosure of HIV status, postpartum depression, and adherence
to ART, as well as maternal health outcomes.
CONCLUSIONS
Research and evaluation to guide clinical and pro-
grammatic practice are urgently needed to make signiﬁcant
progress towards reducing HIV-related maternal deaths and
eliminating preventable maternal mortality in sub-Saharan
Africa. Research priorities include evaluating the impact of
scaled-up access to ART on maternal health outcomes and
improving clinical protocols to prevent and treat the leading
causes of maternal death among WLWH. To generate this
information, causes of maternal death data must be improved,
as must facility-based information on pregnancy-related
outcomes including HIV status, ART use, and maternal
morbidities. Additionally, improving the availability and
accuracy of data from routine program monitoring that
permits analysis of the outcomes of pregnant and postpartum
WLWH is critical.
More evaluation of integrated models of care to
understand how HIV testing, care, and treatment during
antenatal, labor and delivery, and postpartum care can be
better delivered is also important. A nuanced understanding of
program models, including community support systems, which
improve uptake and retention in care and their effects on
maternal morbidity and mortality, is needed. Critical to this
understanding is implementation research on how to incorpo-
rate screening and treatment for tuberculosis and malaria,
preconception counseling, and contraception without sacriﬁc-
ing coverage or quality of other core MCH and HIV services.
Disease burden, causes of maternal deaths at the community
and country level, and the national policy context need to be
considered when identifying which interventions to prioritize.
Successful delivery of integrated MCH and HIV services
requires further health system strengthening, including imple-
mentation research to generate a better understanding of the
optimal mix of skills, stafﬁng, and supportive supervision.
There is an increasing body of compelling evidence
about the social, structural, and psychosocial barriers WLWH
face when deciding to seek and remain in MCH and HIV
care. Less information is available about how to overcome
J Acquir Immune Deﬁc Syndr   Volume 67, Supplement 4, December 1, 2014 Research Priorities for HIV and Maternal Health
 2014 Lippincott Williams & Wilkins www.jaids.com | S255these barriers. Reducing IPV, HIV-related stigma, and
disrespect and abuse in maternity care, and engaging men
hold promise for supporting women to access services and
remain in care and should be evaluated for their effects on the
maternal health of WLWH.
The expert consultation and literature review described
here capture key priorities for research and evaluation to (1)
improve identiﬁcation of and response to leading causes of
maternal death among WLWH and evaluate the effects of
increasing availability of ART on maternal health outcomes,
(2) enhance integrated models for delivery of critical health
interventions to WLWH, and (3) identify interventions that
contribute to an enabling environment for WLWH to begin
and remain in care. Although we endeavored to be compre-
hensive by addressing different factors that inﬂuence maternal
health outcomes (clinical care, models of health service
delivery, and social context) and by including experts with
a broad range of relevant disciplinary backgrounds and
institutional afﬁliations, the scope of the expert consultation
and literature review do not preclude the possibility that
additional critical areas for research and evaluation have been
omitted.
In conclusion, the availability, acceptability, and quality
of maternal health care are life and death issues for pregnant
women. The identiﬁed research and evaluation priorities
focus on the maternal health of WLWH. However, improving
the availability of data on maternal causes of death and
evaluating how best to integrate service delivery to increase
coverage of crucial services and creating an enabling
environment for women to begin and remain in care are
expected to contribute to the maternal health of all women.
The Saving Mothers Giving Life project in Uganda and
Zambia indicates how rapidly progress can be made on
reducing maternal mortality when HIV is addressed as an
integral component of maternal health and resources are
pooled to strengthen existing MCH and HIV platforms to
improve access to and quality of maternal health care.
92
Research and evaluation on maternal health and HIV
can increase collaboration on these 2 global priorities,
strengthen political constituencies and communities of prac-
tice and accelerate progress toward achievement of goals in
both areas. The investments made to reduce maternal
mortality and increase access to HIV treatment in sub-
Saharan Africa are signiﬁcant. The scope of these investments
should be reﬂected in support for research and evaluation that
addresses priority knowledge gaps. As the global community
evaluates progress and prepares for new maternal mortality
and HIV targets, addressing the needs of WLWH must be
a priority now and after 2015.
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